Brain natriuretic peptide (BNP) is an established first line therapy for acute decompensated heart 48 failure (HF), but its efficacy in preventing left ventricular (LV) remodeling after myocardial 49 injury is unknown. The goal of this study was to evaluate the effects of BNP therapy on 50 remodeling following ischemic injury in an awake canine model. Dogs were chronically 51 instrumented for hemodynamics. Ischemia was created by daily coronary embolization (Embo) 52 (3.1 x 10 4 beads/day) for 3 wks; 60 minutes after the first embolization, BNP (100 ng/kg/min) 53 (n=6) or saline (Control) (n=6) was continuously infused via a left atrial catheter for 3 wks. 54
Introduction

8
BNP solution was prepared every day using normal saline. The concentration of BNP for 152 pump infusion was varied and based on the animal's weight as the infusion rate was kept 153 constant at 1 ml/hour. Thus, the concentration of BNP solution (ng/ml) for a particular animal 154 was as follows: 100 (ng/kg/min) x body weight (kg) x 60 (min/hr) x 1 (hr/ml). At the start of 155 infusion, the right atrial tunneled catheter was connected to the continuous infusion pump, which 156 was attached to the back of the dogs using custom-made backpacks. New infusion pumps 157 containing freshly prepared BNP solution or normal saline were connected every day to ensure 158 stability of the solution. 159
The dose of continuous infusion BNP was chosen, in part, based on canine 160 pharmacokinetics of the drug (internal data, data not shown), and, in part, to provide maximal 161 benefit in this pilot experiment and to cause significantly increases in serum cGMP without 162 obvious hemodynamic effects. Published clinical studies have utilized intravenous BNP doses 163 ranging from 10 to 30 ng/kg/min (9,33). As such, the dose used in this experiment was more 164 than double these studies, in order to ensure adequate dosing and maximum effect of 165 downstream BNP signaling. 166
Hemodynamic Measurements and Echocardiography 167
Hemodynamics and echocardiography were measured as previously described (8) . 168 Aortic pressure was measured by attaching the previously implanted catheters to P23ID strain-169 gauge transducers (Statham Instruments, Inc, Oxnard, CA), and LV pressure was measured via a 170 chronically implanted solid pressure gauge. Mean arterial pressure (MAP) was determined on-171 line by use of 3-Hz averaging filters (DA26, Medtron Engineering, Olivenhain, CA). Data was 172 recorded on an eight-channel thermal writing chart recorder (30-V8808-10, Gould Electronics, 173
East Rutherford, NJ), and periods of interest were digitized (a Gateway 2000 486 computer9 equipped with an analog-to-digital conversion system, Sonometric Corp., London, Ontario, 175 Canada) for off-line analysis. Echocardiograms were performed using a Hewlett Packard Sonos 176 5500 at Baseline, after 3 weeks of Embo+Inf, and after 4 weeks of Obs, as previously described 177 (8), and analyzed off-line by a blinded observer. LV mass was calculated using the formula of 178
Devereaux. 179
LV Pressure-Volume Relationship Analysis 180
LV pressure and LV volume were measured at Baseline, after 3 weeks of Embo+Inf, and 181 after 4 weeks of Obs via previously implanted solid state pressure gauges in the LV and 182 sonomicrometric crystals. As previously described (8), LV pressure-volume relationship loops 183
were measured at rest and during a transient preload reduction induced by IVC occlusion; the 184 end-systolic pressure-volume relationship (ESPVR) and end-diastolic pressure-volume 185 relationship (EDPVR) were then calculated. 186
The area between ESPVR and EDPVR at steady state, known as pressure-volume area, is 187 an afterload independent index of pump function that is a predictor of myocardial consumption 188 (39). LV stroke work (SW) was calculated as the integrated area of each PV loop at steady state. 189
Both pressure-volume area and SW were normalized to echocardiographically-determined LV 190 mass, to remove any confounding differences in ventricular size. LV mechanical efficiency was 191 calculated as the ratio of stroke work to PVA (4, 39). Arterial elastance, E a , was calculated as 192 stroke volume/end-systolic pressure. All calculations were made using custom software (Matlab, 193 v6.5). 194
Assessment of Serum cGMP and BNP Levels 195
Blood samples via the implanted aortic catheter for cGMP levels were drawn from two 196 BNP-treated dogs in order to verify BNP-mediated cGMP signaling. In these two dogs, BNP 197 infusion was begun 1 hour prior to embolization, unlike the remaining BNP group. Blood 198 samples were drawn at Baseline, 1 hour after intial BNP infusion but prior to start of 199 Embolization, and then 1 hour after Infusion+Embolization. Two samples were drawn for each 200 animal per time point. 201
Blood samples for BNP levels were also drawn in all Control and BNP-treated dogs at 202
Baseline (prior to Embolization or Infusion), after 1 hour of Embolization alone, after 1 hour of 203 Embo+Inf, after 1 week of Embo+Inf, after 3 weeks of Embo+Inf, and after 4 weeks of 204
observation. 205
All blood samples were drawn while the dogs were laying quietly on the table, and serum 206 was used for cGMP and BNP measurements. The levels of cGMP were measured using the 207 cGMP EIA kit (Cayman Chemical) and BNP levels were measured using a radioimmunoassy kit 208
(Phoenix Pharmaceuticals) 209
Immunohistochemistry and Histology: Fibrosis, Factor VIII, COX-2, and Macrophage 210
Infiltration 211
For immunohistochemical staining, slides were deparaffined and rehydrated in PBS 212 followed by blocking the endogenous peroxidase with 3% hydrogen peroxide. To avoid 213 nonspecific reaction with primary antibody, slides were pretreated with 15% normal goat serum 214 before incubation with primary antibodies. Slides were incubated with primary antibodies 215 including anti-Factor VIII (DAKO, Carpineria, CA, in 1:400), anti-Cox-2 (Novus Biologicals, 216
Littleton, CO, in 1:500) and anti-macrophage, respectively. Normal mouse IgG was used as a 217 negative control. The immunoreactivities were visualized by ABC reagents (Vector, 218
Burlingame, CA) and diaminobenzidine, followed by counterstaining with hematoxylin. 
Hemodynamic Measurements and Echocardiography 246
Hemodynamics at baseline, after 3 weeks of Embo+Inf, and after 4 weeks of Obs are 247 summarized in Table 1 . Baseline hemodynamics and echocardiographic function were 248 comparable prior to embolization in BNP and Control dogs. After 3 weeks of Embo+Inf, the 249 heart failure state was effectively achieved by embolization in both BNP and Control groups, as 250
shown by a 13-14% reduction in MAP, an over 50% increase in LV end-diastolic pressure, and 251 significant decreases in LV dP/dt max ( Tables 3 and 4 . cGMP 283 levels rose almost ten-fold (27.2±8.8 to 187.1±13.9 pmol/ml, p=0.001) after 1 hour of BNP 284 infusion, signifying effective downstream cGMP mediated signaling. After an hour of 285 Embolization+Infusion, cGMP dropped slightly to 127.4±15.9 pmol/ml (p=0.45). Serum BNP 286 levels also confirmed effective drug delivery -BNP levels more than doubled in BNP dogs 287 (4.54±0.06 to 9.66±2.02 ng/ml) after 1 hour of Embolization from Baseline, but decreased to 288 14 5.20±0.66 ng/ml by 3 weeks of Embo+Inf (both p<0.05). BNP levels dropped further in BNP 289 dogs during 4 weeks of Obs, in contrast to Control dogs. 290
Immunohistochemistry and Histology 291
Fibrosis 292
Extensive ischemic myocardial scar in our study was confirmed on fibrosis staining of 293 the ventricular region at risk for ischemia in both Control and BNP dogs. No statistically 294 significant difference was apparent between Control and BNP dogs (20.6 ± 8.8% and 22.8 ± 295
16.3), respectively, measured as percentage fibrosis of ischemic region, p=0.81). 296
Factor VIII Expression 297
A strong trend towards increased Factor VIII expression (important in the regulation of 298 angiogenesis and measured as newly formed vessels per high power field) in the ischemic region 299 was seen in dogs treated with BNP versus Control (p=0.07 vs. Control). 300
COX-2 Expression 301
Expression of COX-2, a marker of systemic inflammation, was significantly lower by 302 immunohistochemical staining in ischemic myocardium treated with BNP compared to 303 myocardium from Control therapy (p<0.05 vs. Control) ( Figure 5 ). Similar to other histologic 304 variables, this effect was limited to the ischemic regions. 305
Macrophage Infiltration 306
No change in macrophage infiltration in ischemic myocardium was seen between BNP 307 and Control therapy dogs at experiment termination (50.2±14.7 vs. 53.2 ± 23.1, p=0.91). 308
309
Discussion 310
Clinical studies thus far have focused on using BNP in the chronic heart failure 311 population. The cardiovascular and renal effects after BNP administration in these studies, as 312 well as its neurohormonal inhibitory properties, suggest that use after myocardial infarction may 313 provide protection against the progression of heart failure. Accordingly, the purpose of the 314 current experiment was to evaluate the long-term effects of continuous intravenous BNP infusion 315 on myocardial performance and remodeling after sustained myocardial injury. We present strong 316 evidence for the first time that short-term, continuous BNP infusion preserves systolic function, 317 prevents LV remodeling, and improves cardiac performance specifically after sustained 318 myocardial injury. BNP therapy also reduced expression of COX-2, thereby altering the 319 inflammatory milieu. These study results justify further investigation addressing use after 320 myocardial infarction. The application of BNP therapy to the acute myocardial infarction 321 population could have important clinical implications on reducing the burden of heart failure on 322 the healthcare system, currently estimated as 2% of health care expenditures (31). 323
Although concern has arisen recently regarding the safety of recombinant BNP (3), 324
numerous earlier clinical reports have demonstrated its clinical benefit. In 2000, Colucci et al. 325 (9) reported a reduction in pulmonary capillary wedge pressure, reduced dyspnea, and less 326 fatigue in patients treated with 6 hours of intravenous nesiritide; these findings were later 327 confirmed by the VMAC trial (33). BNP after cardiac surgery has been studied extensively; 328 short-term intravenous infusion increased cardiac output (14), decreased pulmonary artery 329 pressures (37), and increased urine output (13) in separate small case series. The Nesiritide 330
Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery (NAPA) trial studied 272 331 patients randomized to nesiritide or placebo (28). Contrary to previous studies (36), parameters 332 of renal function were improved, and 180-day mortality was lower than placebo. To our 333 knowledge, only atrial natriuretic peptide has been used immediately after acute myocardial 334 infarction (15, 21): ten days after a 24 hr infusion of ANP administered after first anterior wall 335 acute myocardial infarction, ejection fraction in treated patients increased while LV dimensions 336
were not changed (15), and ANP reduced sympathetic activity two weeks after myocardial 337 infarction two weeks after myocardial infarction in a similar study (21). BNP offers a potentially 338 superior alternative to ANP, as its slightly longer half-life (t 1/2 -22 min), peripheral intravenous 339 route, easy dose-adjustability, rapid onset of action, and documented safety in previous studies 340 (9,13,14,28,33,37) make it an attractive drug in post-AMI patients. Furthermore, BNP is a USA 341 FDA approved drug and its safety profile has been partially established already. 342
Effect of BNP on Myocardial Function 343
Using an extreme myocardial ischemia model, our key findings are as below. First, 344 systolic function was preserved throughout the period of embolization and BNP infusion, as 345 evidenced by the increase in end-systolic elastance and relative preservation of LV dP/dt max 346 compared to Control dogs. Ejection fraction throughout the experiment was higher in BNP-347 treated dogs. Second, stroke work, as measured by pressure-volume loop analysis, provided 348 confirmation that BNP-treated hearts were capable of generating greater external work. Finally, 349 and most importantly, these gains in systolic function were not at the expense of myocardial 350 oxygen consumption, as there was no change in pressure-volume area; this is in direct contrast to 351 dobutamine, which, like BNP, augments contractility but increases mortality versus BNP (38). 352
The consequence of these favorable inotropic findings of BNP was that myocardial efficiency 353 (4), or ratio of stroke work to pressure-volume area and a measure of global cardiac 354 performance, of the BNP-treated hearts was significantly greater than Control hearts. These 355 results are also similar to animal findings by Chen et al. (7) in which subcutaneous BNP, given 356 to dogs with pacing-induced heart failure, showed that cardiac output, pulmonary capillary 357 wedge pressure and systemic vascular resistance were all improved after 10 days of therapy. 358
Myocardial perfusion secondary to coronary vasodilation and cGMP-generated nitric oxide 359 (10,23,29) may also help account for gains in systolic function, lower myocardial oxygen 360 demand, and salvage at-risk myocardium thus reducing infarct size (12). 361
An increase in heart rate was observed during the infusion/embolization period in BNP-362 treated animals which may partially confound the true extent of BNP's effect on contractile 363 function in this study. Conflicting reports exist as to whether intravenous BNP affects heart rate 364 (43,44), but high dose therapy has consistently increased heart rate in most studies (24) and in 365 the setting of ventricular dysfunction (27). We speculate that a concurrent fall in mean arterial 366 pressure, coupled with probable BNP-associated natriuresis, stimulated the baroreceptor reflex, 367 thus driving an increase in heart rate (7,16). Systemic vascular resistance, likewise, falls, and 368 preload is decreased due to significant venodilation; these results create favorable conditions for 369 myocardial energetic and pump function, as reflected in the improvements in ejection fraction, 370 LV dP/dt max , and end-diastolic pressures. However, the effect on heart rate occurred only during 371 BNP infusion, and blood pressure and heart rate equalized among groups after infusion cessation 372 during the 4 week observation period. Most importantly, the gains in cardiac function persisted 373 after BNP infusion cessation, and indices of ventricular remodeling were, in many instances, less 374 pronounced. Furthermore, end-systolic elastance (E es ), a load-independent index, should not be 375 altered with changes in volume status, and was increased in animals treated with BNP, thus 376 supporting the hypothesis that BNP sustains contractile function. Finally, the ability of BNP 377 infusion to interrupt the cycle of heart failure and persist after cessation may suggest intact 378 natriuretic receptor function, unlike the downregulation or unresponsiveness seen in congestive 379 heart failure (32). The ability of BNP therapy to affect the course of heart failure before receptor 380 desensitization occurs argues even more for its use after acute myocardial injury. 381 
Effect of BNP on LV Remodeling
Coronary Embolization Model and Clinical Applicability 428
The coronary-embolization model employed in the current experiment deserves mention. 429
In order to create an extreme and sustained myocardial ischemia state and test whether BNP 430 therapy can overcome the pathology associated with myocardial ischemia induced heart failure, 431 the daily coronary embolization model was chosen: 1) to create hemodynamic derangement that 432 is consistent with heart failure over a three-week time frame, 2) to use a well-known and 433 established model of, specifically, ischemic injury with infarction (22, 35) , and 3) to maintain 434 constant and persistent stimulation for pathologic remodeling through daily embolization. In our 435 experience, simple coronary ligation is not sufficient to create the level of heart failure required 436 to mimic large human myocardial infarction; extensive coronary collaterals aid myocardial 437 recovery in a short time in canines. Furthermore, the specific method of injury, an ischemic 438 insult, was necessary to mimic an appropriate human clinical setting, and was the reason pacing 439 induced heart failure was not used. The coronary embolization model fulfills these criteria, and 440 awake measurements provide reliable and clinically relevant measurements. The study design 441 was intended to replicate symptom onset to response by medical personnel, with induction of 442 injury first, followed by administration of BNP after 60 minutes. The model does not replicate 443 the physiology of reperfusion after revascularization or acute infarction -rather, it replicates 444 remodeling that occurs after a severe prolonged infarction or repeated infarction without 445 revascularization. The study findings, therefore, represent the most extreme form of acute 446 21 ischemic myocardial injury, and it is plausible that improvement in this model also translates to 447 improvement in less severe ischemic injury. 448
Conclusions 449
In conclusion, acute myocardial injury was created in awake dogs using daily coronary 450 embolizations. Continuous intravenous BNP therapy preserved systolic function and attenuated 451 LV remodeling, supported by both energetic and biochemical mechanisms. These results 452 provide a rationale for prolonged intravenous BNP treatment after myocardial infarction with the 453 goal of prevention of the chronic heart failure state. 
